Short answer
Dyne Therapeutics, Inc. (DYN) filed an 8-K current report with the SEC on June 3, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Full enrollment completed for the registrational expansion cohort in the Phase 1/2 ACHIEVE trial.
Dyne Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Full enrollment completed for the registrational expansion cohort in the Phase 1/2 ACHIEVE trial
- Z-basivarsen targets myotonic dystrophy type 1, supporting progression toward potential registration
- Press release furnished as Exhibit 99.1, containing additional trial and program details
Item 8.01 · Other Events
- ACHIEVE Phase 1/2 registrational expansion cohort fully enrolled with 71 DM1 participants
- Topline REC data targeted for Q1 2027, supporting potential U.S. Accelerated Approval BLA filing in Q3 2027
- BLA strategy includes REC data plus enrolled multiple-ascending-dose and long-term extension participants
- Potential z-basivarsen launch targeted for H1 2028, contingent on Priority Review and FDA approval
- Regulatory timing remains uncertain, with clinical, FDA interpretation, approval-pathway, and funding risks identified
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dyne Therapeutics, Inc. 8-K filings
Get the next DYN 8-K as it lands
Follow DYN for push alerts, or ask the research agent what this filing means.